Screening of Siddha Herbal Formulation Maramanjal Kudineer Churnam Against COVID-19 Through Targeting of Main Protease and RNA-Dependent RNA Polymerase of SARS-CoV-2 by Molecular Docking Studies

62 Pages Posted: 4 Aug 2020 Last revised: 6 Aug 2020

See all articles by Jerad Suresh

Jerad Suresh

Madras Medical College - Department of Pharmaceutical Chemistry

Kumudhaveni B

Madras Medical College - Department of Pharmaceutical Chemistry

Soundarya S

Madras Medical College

Priyadharshini G

Madras Medical College

Noorulla K M

Arsi University

Date Written: July 23, 2020

Abstract

Background: Corona virus disease (COVID-19) is an infectious pandemic disease caused by the newly discovered novel corona virus. It was first diagnosed in Wuhan, China. COVID-19 virus spreads by droplets of saliva or discharge from the nose of the infected person via coughs or sneezes. Recently on 07/07/2020 WHO acknowledged “Evidence emerging” of the airborne spread of the corona virus. According to WHO, globally as on 10/07/2020 05.30 GMT +5.30, there have been 1,20,15,193 confirmed cases of COVID-19 and 5,49,247 deaths reported. Currently, there is no specific treatment approved for COVID-19, although treatment and vaccines are under study. In India, Department of AYUSH promotes the Indian system of Medicine to treat COVID-19 and recommends the use of anti-viral Siddha formulations Nilavembu Kudineer and Kabasura Kudineer. The present study aims to work on Siddha formulation Maramanjal Kudineer Churnam (MKC) a step towards treatment for the COVID-19 and to create a scientific evidence for the use of MKC.

Methods: Seventy-four phytoconstituents of the MKC formulation was selected for the molecular docking studies to act on two critical targets main protease and SARS-CoV-2 RNA-dependent RNA polymerase. The molecular docking study was performed by using MGL Tools 1.5.6.

Results: Docking studies on the data set of 74 phytoconstituents present in MKC, 74 phytoconstituents developed a docking results against the target COVID-19 main protease and 74 phytoconstituents developed a docking results against the target SARS-CoV-2 RNA-dependent RNA polymerase.

Conclusion: This research has concluded that the MKC has the lead molecules that inhibits COVID-19’s target of Main Protease of COVID-19 and SARS Cov-2 RNA-dependent RNA polymerase.

Note: Funding: None to declare

Declaration of Interest: None to declare

Keywords: Siddha Formulation, Maramanjal Kudineer, SARS-CoV-2, AutoDock, Proteins

Suggested Citation

Suresh, Jerad and B, Kumudhaveni and S, Soundarya and G, Priyadharshini and Kaveripakkam Mohammed Ali, Noorulla, Screening of Siddha Herbal Formulation Maramanjal Kudineer Churnam Against COVID-19 Through Targeting of Main Protease and RNA-Dependent RNA Polymerase of SARS-CoV-2 by Molecular Docking Studies (July 23, 2020). Available at SSRN: https://ssrn.com/abstract=3659092 or http://dx.doi.org/10.2139/ssrn.3659092

Jerad Suresh

Madras Medical College - Department of Pharmaceutical Chemistry ( email )

India

Kumudhaveni B

Madras Medical College - Department of Pharmaceutical Chemistry ( email )

India

Soundarya S

Madras Medical College ( email )

Priyadharshini G

Madras Medical College ( email )

Noorulla Kaveripakkam Mohammed Ali (Contact Author)

Arsi University ( email )

Asella
Ethiopia

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
235
Abstract Views
1,961
Rank
236,407
PlumX Metrics